

**ANTIFUNGAL TYPING OF BIOFILM PRODUCING
Candida albicans ISOLATED FROM ORAL CAVITY
OF DIABETIC AND NON-DIABETIC POPULATION
OF DHARAN, NEPAL**



A

Dissertation

Submitted to the **Department of Microbiology,**
Central Campus of Technology Tribhuvan University, Dharan,
Nepal, in Partial Fulfillment of the Requirements for the Award of
Degree of Masters of Science in Microbiology
(**Medical**)

By:

Bijay Kumar Shrestha

Department of Microbiology

Central Campus of Technology, Dharan, Nepal

T.U. Regd. No.: 5-2-8-22-2010

2018

©Tribhuvan University

RECOMMENDATION

This is to certify that **Mr. Bijay Kumar Shrestha** has completed this dissertation work entitled “**Antifungal Typing of Biofilm Producing *Candida albicans* Isolated from Oral Cavity of Diabetic and Non-Diabetic Population of Dharan, Nepal**” as a partial fulfillment of the requirement of M.Sc. degree in Microbiology (Medical) under my supervision. To our knowledge, this work has not been submitted for any other degree.

.....
Hemanta Khanal

(Supervisor)

Assistant Professor

Department of Microbiology

Central Campus of Technology

Hattisar, Dharan, Nepal

CERTIFICATE OF APPROVAL

On the recommendation of Asst. Professor **Mr. Hemanta Khanal** this dissertation work of **Bijay Kumar Shrestha** entitled “**Antifungal Typing of Biofilm Producing *Candida albicans* Isolated from Oral Cavity of Diabetic and Non-Diabetic Population of Dharan, Nepal**” has been approved for the examination and is submitted for the Tribhuvan University in Partial fulfillment of the requirements for M. Sc degree in Microbiology (Medical).

.....
Mr. Shiv Nandan Sah
Asst. Professor
Head of Department
Department of Microbiology
Central Campus of Technology
Tribhuvan University,
Dharan

.....
Mr. Hemanta Khanal
Asst. Professor
M. Sc. Microbiology Coordinator
Department of Microbiology
Central Campus of Technology
Tribhuvan University,
Dharan

Date:/...../.....

BOARD OF EXAMINERS

Recommended by:

Asst. Professor Mr. Hemanta Khanal

Supervisor

Approved by:

Mr. Prince Subba

M.Sc. Programme Coordinator

Examined by:

()

Internal Examiner

.....

()

External Examiner

Date:/...../.....

ACKNOWLEDGEMENTS

I would like to express my heartfelt gratitude to my respected supervisor **Asst. Professor Mr. Hemanta Khanal** for his continuous support, guidance and encouragement throughout my research work. It would not have been possible to complete this dissertation work successfully without his valuable help.

I am very much obliged to my Campus Chief **Professor Dr. Dhan Bahadur Karki, Mr. Prince Subba**; M.Sc. Programme Coordinator, **Asst. Prof. Shiv Nandan Sah**; Head of Department of Microbiology, Central Campus of Technology for providing me with the required facilities and instructions for the dissertation work.

I am also thankful to all the teachers especially **Asst. Professor Mr. Suman Rai** and laboratory staff **Ain Bahadur Karki, Prajwal Bhandari**, librarian **Mr. Om Khatiwada** and library staff for their great cooperation and help.

Additionally, I would express my gratitude to my classmates, especially **Jenish Shakya, Bidhya Dhungana, Manita Subba** and **Jenisha Dahal** for their help and support.

Finally, I would like to convey my regards to my family members for motivating and supporting me during the thesis work.

.....
Bijay Kumar Shrestha

Date:/...../.....

ABSTRACT

Candida are almost universal on normal adult skin and *C. albicans* is part of the normal flora of the mucous membranes of the respiratory, gastrointestinal, and female genital tracts. *Candida albicans* is normal flora, lives in 40- 80% of the human population with no harmful effects. It is acknowledged that diabetic patients are more susceptible to infections caused by *Candida albicans* due to increased blood glucose and inability of immune system in eradicating the fungus. Studies suggest that Gutkha consumers are also at high risk of oral *Candida* carriage because of poor Oral hygiene. The oral rinse was inoculated onto the Sabouraud dextrose agar with Chloramphenicol and was incubated at 37°C for 3-4 days. *Candida* colonies were counted. *Candida albicans* were identified by Germ tube test. This study reported 31.5 % prevalence of oral *Candida*. Out of 63 positive samples of *Candida*, 42 isolates were known to be *Candida albicans*. The *Candida* carriage in CFU of diabetic population was statistically significant ($p < 0.001$). The maximum isolates were found to be Biofilm producers. There was significant association between Gutkha consumers with oral *Candida* carriage. The study suggests that there is higher colonization of *Candida* in diabetic populations than in healthy population. The result also concludes that frequency of *Candida* in Oral cavity of Gutkha consumers is also higher ($p = 0.041$). All isolated strains of *Candida albicans* were tested for antifungal susceptibility testing by using Kirby Bauer disk diffusion method 76.19% were found to be Resistant to Fluconazole and 50% were found to be resistant to Amphotericin B. There was statistical significance in Biofilm formation and fluconazole Drug resistance. The highest prevalence of oral *Candida* was found to be in diabetic population and in Gutkha consumers. The greatest numbers of isolated *Candida albicans* were biofilm producer which showed greater frequency of Fluconazole drug resistance. Microtitre method was considered efficient method for screening biofilms.

Keyword: *Candida*, Biofilm, Drug Resistance

TABLE OF CONTENTS

Title	Page No
Title page	i
Recommendation	ii
Certificate of Approval	iii
Board of Examiners	iv
Acknowledgement	v
Abstract	vi
Table of contents	vii-x
List of Abbreviations	xi
List of Tables	xii
List of figures	xiii
List of Photographs	xiv
List of Appendices	xv
List of Abbreviations	xii-xiii
Chapter I	1-6
Introduction	1-5
Objectives	6
CHAPTER II	7-21
LITRATURE REVIEW	7-21
2.1 <i>Candida</i>	7
2.2 Classification of <i>Candida</i>	8
2.2.1 Classification on the basis of pigment production	8
2.3 Characteristics of <i>Candida albicans</i>	8

2.3.1 Colony characteristics	9
2.4 Virulence factors	9
2.4.1 Adhesins	10
2.4.2 Invasins	10
2.4.3 Heat shock proteins	9
2.4.4 Biofilm formation	10
2.4.5 Secreted hydrolase	11
2.4.6 Metabolic adaption	11
2.4.7 Cell wall associated factors	12
2.5 Pathogenicity	12
2.6 Oropharyngeal Candidiasis	13
2.7 <i>Candida</i> colonization of oral cavity	14
2.8 Promoting factor of <i>Candida</i>	14
2.8.1 Local factor promoting Candidiasis	15
2.9 Clinical presentations of oral Candidiasis	15
2.9.1 Localized oral infections	15
2.9.2 Oropharyngeal Candidiasis	15
2.9.3 Vulvovaginal (genital) Candidiasis	16
2.9.4 Invasive candidiasis (Candidemia)	16
2.10 Mechanism of Resistance	16
2.11 Prevalence of <i>Candida</i> in the community	17
2.12 Sources and transmission of <i>Candida</i>	17
2.13 Clinical presentation	18
2.14 Action of antifungal drugs	18
2.14.1 Polyenes	18
2.14.2 Azoles	19

2.15 Resistance	19
2.15.1 Biofilm	19
2.15.2 Mechanisms of <i>Candida albicans</i> resistance to antibiotics	20
2.16 Host immune response	20
2.17 Prevention and treatment	20-21
Chapter III: Materials and Methods	22-27
3.1 Materials	22
3.2 Methods	22
3.2.1 Place of study	22
3.2.2 Sample size and types	22
3.3 Sample collection	22
3.4 Culture of oral rinse in SDA	23
3.5 Assessment of <i>Candida</i> colonization by quantitative enumeration of <i>Candida</i>	24
3.6 Identification of isolates	24
3.7 Characterization	25
3.7.1 Haemolysin assay	25
3.7.2 Screening impact of diabetic on haemolytic activity	25
3.7.3 Screening <i>Candida albicans</i> for production of phospholipase	25-26
3.8 Biofilm assays	26
3.8.1 Microtitre plate method	26
3.8.2 Tube method	26-27
3.8.3 Congo red agar method	27
3.9 Antifungal susceptibility testing	27
3.10 Quality control for the test	27
3.11 Data analysis	27
Chapter IV: Results	29-40
4.1 Gender wise distribution of <i>C. albicans</i> in sample population	29

4.2 Age wise distribution of <i>Candida albicans</i> in sample population	30
4.3 Comparative study of <i>Candida</i> isolated from different populations	31
4.4 Comparative study of <i>Candida albicans</i> isolated from different Populations	32
4.5 Prevalence of <i>Candida</i> in population	33
4.6 Antifungal susceptibility pattern of <i>Candida albicans</i> isolates	34
4.7 Phospholipase and Hemolysis assay	35
4.8 Biofilm assay by microtitre plate method	36
4.9 Comparative study of biofilm assays	37
4.10. Comparative study of biofilm formation and antifungal drug resistance	38
4.11. Sensitivity and specificity of biofilm screening methods	40
CHAPTER V: DISCUSSION	41-47
CHAPTER-VI: CONCLUSION AND RECOMMENDATIONS	48-49
6.1 Conclusion	48
6.2 Recommendations	49
References	50-65
Appendices	I-XIII

LIST OF TABLES

- Table 1: Comparative study of *Candida* isolated from different population
- Table 2: Comparative study of *Candida albicans* isolated from different Populations
- Table 3: Antifungal susceptibility pattern of *Candida albicans* isolates
- Table 4: Hemolysin and phospholipase index of *Candida albicans*
- Table 5: Comparative study of haemolysin degree
- Table 6: Biofilm assay by microtitre plate method
- Table 7: Biofilm formation by *Candida albicans* by three methods
- Table 8: Comparative analyses of biofilm formation and antifungal drug resistance
- Table 9: Biofilm formation and Amphotericin B drug resistance
- Table 10: Biofilm formation and Fluconazole drug resistance
- Table 11: Sensitivity and specificity of biofilm screening methods

LIST OF FIGURES

Figure No:	Title of Figure
Figure 1:	Gender wise distribution of <i>Candida albicans</i>
Figure 2:	Age wise distribution of <i>Candida albicans</i>
Figure 3:	Prevalence of <i>Candida</i> in Population
Figure 4:	Biofilm formation and Amphotericin B drug resistance
Figure 5:	Biofilm formation and Fluconazole drug resistance

LIST OF PHOTOGRAPHS

Photograph No.1 Colonies of *Candida* from diabetic and healthy population

Photograph No.2 Biofilm of *Candida albicans* in microtitre wells

Photograph No.3 Antifungal susceptibility test

Photograph No.4 Hemolysis degree.

Photograph No.5: Sample collection

Photograph No.6: Sample processing in the Microbiology Lab

LIST OF APPENDICES

- APPENDIX – I NHRC approval letter
- APPENDIX – II Materials and equipment
- APPENDIX – III Mycological media
- APPENDIX – IV Reagents/stains
- APPENDIX – V Staining procedures and Antifungal susceptibility test
- APPENDIX – VI Questionnaire sheet for oral sample collection
- APPENDIX – VII Statistical analysis
- APPENDIX – VIII Formulas

LIST OF ABBREVIATIONS

AMR	: Antimicrobial Resistance
ATCC:	American Type Culture Collection
CLSI:	Clinical and Laboratory Standards Institute
DNA:	Deoxyribonucleic Acid
ELISA:	Enzyme Linked Immunosorbent Assay
KDa:	Kilo Dalton
MDR:	Multidrug Resistance
MIC:	Minimum Inhibitory Concentration
NCCLS:	National Committee for Clinical Laboratory Standards
SDA:	Saboured Dextrose Agar
WHO:	World Health Organization
TCP:	Tissue Culture Method
TM:	Tube Method
CRA:	Congo Red Agar
DM:	Diabetic mellitus
OD:	Optical Density

CHAPTER I

INTRODUCTION AND OBJECTIVES

1.1 Background

Candida albicans is known to be normal flora of human body harboring skin and mucosal cavity. It is found to be present in oral, vaginal mucosa and known to colonize 60% of healthy population (Lamont et al 2006). The human saliva contains a great number of microorganisms (approximately 10^8 per ml). Most of the microorganisms in the saliva are derived from other parts of the oral cavity such as the teeth and oral mucosal surfaces as a result of mechanical abrasion caused by chewing, talking and swallowing. The micro vascular changes and possibly increased glucose concentration in the saliva and gingival crevicular fluid which might contribute in declining pH of saliva resulting in acidogenic microorganism substrate and plaque formation *Candida albicans* is dimorphic fungi occurring in both yeast and hyphae form. It is spherical–oval fungi measuring 5-50 um by 2-5 um in diameter in hyphae and 5-25 um in yeast form (Kasper et al 2005). Studies have suggested that *Candida albicans* are associated with number of opportunistic infections in immunocompromised patients like in HIV patients, cancer patients and diabetic patients etc. In diabetes mellitus type–II there has been known greater incidence of oral candidiasis which could be associated with immune dysfunction caused by high glucose concentration in blood, tissue and saliva (Obradovic R 2011).

Candida has known to be opportunistic pathogen under immunosuppression and tobacco chewing conditions (Javed et al 2014; Hsia et al 1981). It is suggested that individuals chewing Gutkha are susceptible to oral *Candida* infections than non-chewers (Abduljabbar et al 2017). Chewing Tobacco that includes Gutkha, Betel quid (BQ) which is common habit in South Asian nations like in India, Pakistan, Bangladesh, Sri lanka and Nepal (Javed et al 2010). Betel quid is mixture of areca-nut, lime enveloped in piper betel leaf whereas Gutkha is found

in Sachet (Javed et al 2013). The possible Explanation for greater *Candida* colonization in Gutkha consumers could be due to the presence of nicotine and hydrocarbons such as polycyclic aromatic hydrocarbons acting as nutrient for Oral yeast facilitating its growth (Abduljabbar, Hussain et al 2017; Hasia et al 1981)

Candida albicans pathogenesis is described by its host defense mechanism, adherence, and production of tissue degrading hydrolytic enzymes like protease, phospholipase and haemolysin and role in biofilm production on host tissue and in medical devices (Silva et al 2011). Biofilm production is associated with the role of fungi to evade host immune function. Biofilm overcome adhesions to host cell molecules resist antifungal therapy making the treatment of infection more complicated (Ozkan et al 2005).

Diabetes mellitus also known as hyper glycaemia is the disease resulted by failure of metabolism of blood glucose by insulin hormone. The World Health Organization (WHO) has expected an increasing development of diabetes to more than 300 million by the year 2025; particularly, with type 2 diabetes mellitus. There lies the incidence of oral candidiasis in diabetic patients. DM is a highly prevalent worldwide, disorder characterized by a relative or absolute insufficiency of insulin secretion and/or concomitant resistance to the metabolic action of insulin on target tissues (Garber 1998).

The significant difference in *Candida* species colonization was found between patients with diabetes (75.0%) and controls (35.1%) ($P < 0.05$) (Bartholomew 1987). Alzarea et al (2015) reported a significant relationship between prevalence of *Candida* and oral hygiene where good oral hygiene attributed to least colonization by candida albicans. Pallavan et al (2014) reported that diabetic patients had higher prevalence of colonization by *Candida albicans* where they reported that increased glucose tissue level could have facilitated growth of yeast.

Lamichhane et al (2015) found that there was significant increase in CFU of candida albicans among diabetic patients than in non-diabetic individuals. They

reported a comparison of oral candida carriage in diabetic patients and control group where *Candida's* CFU were higher in sample from diabetic patients. The oral candidiasis is significantly more frequent in diabetic patients compared to the non-diabetic subjects (Obradovi et al 2011).

Patients with poor glycemic control are being particularly prone to severe and/or recurrent bacterial or fungal infections (Manfredi et al 2004). The opportunistic fungal infections including oral candidiasis are seen as early non-specific signs of uncontrolled Diabetes (Sykes et al 2001). Candidiasis has been known the most common mycosis of the oral cavity of both healthy and immunodeficient persons. It is a superficial opportunistic infection, essentially facilitated by local and systemic predisposing factors. The commonality of this disease is probably because 40-60% of healthy individuals harbor commensal *Candida* in the oral cavity, without any signs or symptoms of candidiasis (Soysa et al 2005).

A number of factors are known associated with oral carriage of *Candida* in diabetic patients, like the type and duration of the diabetes, the degree of glycemic control, (Hill et al 1989) and denture wearing (Dorocka-Bobkowska et al 1996). Patients with poor glycemic control are being particularly prone to severe and/or recurrent bacterial or fungal infections (Manfredi et al 2004).

Candida albicans exhibits hemolytic activity when grown on glucose-enriched blood agar. This activity is present on intact organisms, and it is secreted into the culture medium. Hemoglobin released from lysed erythrocytes can restore the transferrin-inhibited growth of *C. albicans*. In humans, most of the iron is located intracellular as ferritin or as heme-containing compounds. It is concluded that *C. albicans* expresses a hemolytic factor which allows it to acquire iron from host erythrocytes (Manns et al 1994).

Virulence in *C. albicans* and other pathogens includes host recognition, which enables the pathogen to bind to host cells and proteins. Additionally, degradative enzymes play a special role in virulence. Fungal invasion is facilitated more by

the transition between yeast cells and filamentous growth than by yeast growth (Cullen & Sprague, 2012).

The production of haemolysin plays an important role in virulence. This protein is essential for survival and is related to the acquisition of iron (Vaughn & Weinberg, 1978). Haemolysins are proteins produced by micro-organisms to destroy red blood cells. Iron, an inorganic element, is essential for the development of micro-organisms, including yeasts, and the ability to obtain this element is essential for the establishment of an infectious process (Manns et al., 1994).

Seven phospholipase genes have been identified (PLA, PLB1, PLB2, PLC1, PLC2, PLC3 and PLD1); however, the role of the enzymes encoded by these remains unclear (Samaranayake et al., 2006). PLB1 has been described as having a virulence role in animal models of candidiasis. Plb1p is an 84 kDa glycoprotein present at hyphal tips during tissue invasion and has hydrolase and lysophospholipase-transacylase activity (Ghannoum, 2000).

The biofilm and the formation of an extracellular matrix, results the difficulty for the antifungal agents to reach yeast cells and shields from environment. The main antifungal mechanism is mediated by efflux pump and presences of subpopulation of perister cells are known (Douglas 2003; Ramage et al 2006).The studies indicated that the Antifungal drug resistance develops with the Biofilm maturation (Chandra et al 2001).

Oropharyngeal candidiasis is an infection in the mouth and throat area. Usually, it is characterized by the formation of white patches on top of the tongue and throughout the mouth, which is also known as “thrush”. Candidal proteolytic enzymes, toxins and phospholipase in also studied in determining the virulence of the yeast. Secreted aspartic proteinases (Saps) are expected to overcome function during mucosal or disseminated infections. Mycotoxin may act to inhibit phagocytic activity or suppress the local immune system (Naglik 2003).

There are multiple mechanisms of azole resistance in *C. albicans* including mutations in the gene ERG11 involved in ergosterol biosynthesis and the overexpression of drug efflux pumps (White et al 2002). ATP-binding cassette (ABC) pumps and the major facilitator superfamily (MFS) transporters are the two main families of the efflux protein. Azoles target the 14 α -demethylase enzyme encoded by ERG11, blocking ergosterol biosynthesis. This leads to depletion of ergosterol, thus inducing the accumulation of intermediates from the toxic sterol pathways, which inhibit growth (Ramage et al 2012). High-level azole resistance is caused by the overexpression of ABC efflux pumps in the plasma membrane (Cannon et al 2009).

Clinically, oral candidiasis may present as pseudomembranous candidiasis, erythematous candidiasis, hyperplastic candidiasis, denture-associated erythematous candidiasis, angular cheilitis, median rhomboid glossitis and chronic mucocutaneous candidiasis (Napenas et al 2009; Farah et al 2010).

1.2. Objectives

1.2.1 General Objective

- To assess antifungal susceptibility of biofilm producing *Candida albicans* isolated from oral cavity of diabetic and non-diabetic population of Dharan, Nepal.

1.2.2 Specific Objectives

- i. To determine the carriage rate of oral *Candida* carriage among diabetic and non-diabetic patients.
- ii. To assess the antifungal susceptibility test.
- iii. To determine hemolytic activity and phospholipase activity of *Candida albicans*.
- iv. To assess the ability of biofilm production.

CHAPTER II

LITERATURE REVIEW

2.1 *Candida albicans*

Candida albicans is a member of the normal human microbiome. *Candida* are almost universal on normal adult skin and *C. albicans* is part of the normal flora of the mucous membranes of the respiratory, gastrointestinal, and female genital tracts. In most individuals, *C. albicans* resides as a lifelong, harmless commensal. Under certain circumstances, however, *C. albicans* can cause infections that range from superficial infections of the skin to life-threatening systemic infections (Francois et al 2013). *C. albicans* is adept at adhering to catheters and various indwelling medical implants, and is currently ranked by the Center for Disease Control as the third most commonly isolated bloodstream pathogen in hospitalized patients with a mortality rate of up to 50% (Mayer et al 2005).

Candida albicans ability to utilize iron for multiplication in host tissue has been suggested a virulent role by producing Hemolysin. *Candida* species hemolytic activity was found higher in human blood enriched SDB supplemented by 3% glucose. The result suggested a strong relation of increased blood sugar level in diabetes contributing to increased hemolytic activity of yeast (Malcok et al 2009). In Nepal, Subramanya et al (2017) reported out of the total of 71 isolates we obtained, 48 (67.6%) were *Candida albicans*. Sharma et al (2017) could isolate all the species of *Candida*, namely, *Candida albicans*, *Candida glabrata*, *Candida dubliniensis*, *Candida krusei*, *Candida parapsilosis* except *Candida tropicalis* which showed significantly higher ($p < 0.001$) occurrence in the diabetic group patients in comparison to the healthy individuals.

The human saliva contains a great number of microorganisms (approximately 10^8 per ml). Most of the microorganisms in the saliva are derived from other parts of the oral cavity such as the teeth and oral mucosal surfaces as a result of mechanical abrasion caused by chewing, talking and swallowing. The micro

vascular changes and possibly increased glucose concentration in the saliva and gingival crevicular fluid which might contribute in declining pH of saliva resulting in acidogenic microorganism substrate and plaque formation. As a Result of that, the increased growth of acidogenic microorganisms such as *Candida albicans* will had a prominent role in developing various oral complications (Touger 1996).

2.2 Classification of Candida

The genus *Candida* includes around 154 species among which about six species are dominantly and frequently isolated from human infections. The most common pathogens considered as causative agent of *Candida* infections are *Candida albicans*, *Candida tropicalis*, *Candida glabrata*, *Candida parapsilosis*, *Candida glabrata* and *Candida Krusei*. Patients receiving fluconazole are at risk of developing infections due to fluconazole resistant *Candida krusei* and *Candida glabrata* strains (Kasper et al 2005).

2.2.1 Classification on the basis of pigment production

Candida species can produce various pigmentation when grown in CHROM Agar media (Kasper et al 2005).

Candida Species	: colony characteristics
<i>Candida albicans</i>	: green
<i>Candida tropicalis</i>	: metallic blue
<i>Candida krusei</i>	: Pink, fuzzy
other Species	: white to mauve

2.3 Characteristics of *Candida albicans*

The colonies of *Candida* spp. are cream colored to yellowish, grow rapidly and mature in 3 days. The texture of the colony may be pasty, smooth, glistening or dry, wrinkled and dull, depending on the species (Kasper et al 2005).

Candida species can be characterized by ability of Germ tube formation test usually shown by *Candida albicans*, *Candida dubliensis* and *Candida tropicalis*. *Candida* species can all grow in budding yeast from Characterization of *Candida* species by a germ-tube formation test *Candida* (blastospores). These budding yeast cells are spherical or oval in shape and are approximately 2.5 x 3.7 µm in size. However, some *Candida* species are pleomorphic and can grow in different growth forms during pathogenesis in humans or in other stress-induced media as a means to compensate for the changing conditions in the new environment (Kasper et al 2005).

Chlamyospore formation is another morphological diagnostic tool routinely used in the medical mycology laboratory to distinguish between two closely related candidal pathogens, *C. albicans* and *C. dubliniensis*, whose natural habitat is the human host (Pfaller et al 2014). Cultures carried out on *C. albicans* and *C. dubliniensis* in vitro by other authors on certain nutrient deficient media in the dark at 25°C under microaerophilic conditions also yielded chlamyospores. Chlamyospores are inter-calary, terminal spores that are formed by the rounding-off of cells in growing hyphae. The transition between yeast and hyphal growth forms is termed dimorphism and it has been proposed that both growth forms are important for pathogenicity (Jacobsen et al 2012).

2.3.1 Colony Characteristics

Colonies on SDA is creamy, pasty colonies, smooth after 24-48 hours at 25-37°C. In blood agar the colonies are white creamy (Kasper et al 2005).

2.4 Virulence factors

Candida albicans is a polymorphic fungus that can grow in several different forms, primarily yeast, pseudo hyphae, and hyphae. For its pathogenicity, its ovoid-shaped budding yeast and parallel-walled true hyphae forms are the most important.

2.4.1 Adhesins

Candida albicans have special sets of glycosylphosphatidylinositol (GPI)-linked cell surface glycoproteins that allow it to adhere to the surfaces of microorganisms. These glycoproteins are encoded by 8 sets of agglutinin-like sequence (ALS) genes, ranging from Als1-7 and Als9. For adhesion, the Als3 gene appears to be the most important as it is up regulated during an infection of oral and vaginal epithelial cells. Also, it helps with biofilm formation by helping with adhesion to each other (Murciano et al 2012).

2.4.2 Invasins

Along with adhesion, Als3 proteins can function as invasins that help with the invasion of *C. albicans* into host epithelial and endothelial cells. Another important invasin gene is Ssa1, which normally codes for heat-shock proteins. Basically, these specialized proteins on the pathogen's surface mediate binding to host ligands, such as E-cadherin on epithelial cells and N-cadherin on endothelial cells, and it induces host cells to engulf the fungal pathogen. Another method of invasion is the active penetration of *C. albicans* into host cells by an unknown mechanism involving hyphae (Wachtler et al 2011).

2.4.3 Heat shock proteins

The heat shock response is a conserved reaction of living organisms to stressful conditions such as high temperature, starvation and oxidative stress (Lindquist et al 1992).

2.4.4 Biofilm formation

Candida albicans have the ability to form biofilms on living and non-living surfaces, such as mucosal membranes and catheters, respectively. After the adherence of yeast cells to the surface, there is development of hyphae cells in the upper part of the biofilm. Eventually, this leads to a more resistant, mature biofilm and the dispersion of yeast cells – both contributing to the pathogen's virulence. In the process of biofilm formation, Bcr1, Tec1 and Efg1 function as important

transcriptional factors (Fanning et al 2012). Recent studies show that biofilms protect *C. albicans* colonization from neutrophil attack and deter the formation of reactive oxygen species (Xie et al 2012).

2.4.5 Secreted hydrolases

Candida albicans secrete 3 main classes of hydrolases: proteases, phospholipases and lipases. It is proposed that these hydrolases help facilitate the pathogen's active penetration into host cells and the uptake of extracellular nutrients from the environment. There are about 10 known secreted aspartic proteases (Sap1-10), and their exact contribution to pathogenicity is controversial. For phospholipases, there are 4 major classes (A, B, C, and D), and all 5 members of the B class are involved with the disruption of a host cell surface. Thirdly, lipases are consisted of 10 members (LIP1-10), and studies show that there is decreased virulence in their absent (Wachtler et al 2012).

2.4.6 Metabolic adaption

Candida albicans are usually found in the gastrointestinal microbiome of healthy individuals, and in this environment, nutrient levels are relatively high. However, during niche changes in the course of an infection, available nutrient levels will also change. Consequently, the fungus can quickly undergo metabolic adaption, such as their glycolysis, gluconeogenesis, and starvation responses (Brock 2009). For example, in the case of candidemia, *C. albicans* infect the bloodstream, which is typically rich in glucose. Nevertheless, it might be phagocytosed into a macrophage or neutrophil. In response, *C. albicans* quickly switch from its glycolysis to starvation response with the activation of the glyoxylate cycle. Due to this flexibility, *C. albicans* can infect almost every organ in a human host through the bloodstream, providing candidemia's higher mortality rate (Brock 2009)

2.4.7 Cell wall associated factors

The cell wall composition of *C. albicans* is 90% carbohydrate and 10% protein. The fibrillar outer layer consists of mannoproteins, while the β -glucans/chitin layer lies underneath the mannoprotein, with both providing strong support to the cell wall. The outer cell wall consists of mannans that are less structured and permeable thus affecting the cell resistance against antifungal agents. The carbohydrate in the cell walls not only induces the immune response of the host, but also induces hyperactivity of the inflammatory response causing pathogenicity of the *C. albicans*. The transition of *C. albicans* from colonizing organism into pathogenic organism involves multiple complex pathways (Gow and Hube 2012).

2.5 Pathogenicity

Pathogenicity of the *Candida* is determined by the ability to change the normal flora to opportunistic pathogen by dropdown of host immune response. Adherence is known to be important virulence factor that is mediated by specific (ligand receptor interactions) and non-specific (electrostatic charge, van der Waals forces) mechanisms by which the yeast attaches to different tissue types and inanimate surfaces (Cotter et al 2000).

Candida is dimorphic fungi that exist in different phenotypes in human. Blastospores phenotypic form is known to be responsible for transmission and spread, and the mycelial form of germinating yeast is known to be tissue invasive form. However, both blastoconidia and (pseudo) hyphae are capable of destroying superficial cells by direct invasion (Sobel 1984).

Along with adhesion, Als3 proteins can function as invasins that help with the invasion of *C. albicans* into host epithelial and endothelial cells. Another important invasin gene is Ssa1, which normally codes for heat-shock proteins. These specialized proteins present on the pathogen's surface mediate binding to host ligands, such as E-cadherin on epithelial cells and N-cadherin on endothelial cells, and it induces host cells to engulf the fungal pathogen. Another method of

invasion is the active penetration of *C. albicans* into host cells by an unknown mechanism involving hyphae (Wächtler et al 2011).

2.6 Oropharyngeal Candidiasis

Oropharyngeal candidiasis is an infection in the mouth and throat area. Usually, it is characterized by the formation of white patches on top of the tongue and throughout the mouth, which is also known as “thrush”. Candidal proteolytic enzymes, toxins and phospholipase are also studied in determining the virulence of the yeast. Secreted aspartic proteinases (Saps) are expected to overcome function during mucosal or disseminated infections. Mycotoxin may act to inhibit phagocytic activity or suppress the local immune system (Naglik 2003).

Oral candidiasis *Candida* species are part of the normal oral flora and the most commonly identified pathogen is *C. albicans* (Manfredi et al 2002). A simplistic explanation for the increased carriage rates in diabetic patients is the increase in salivary glucose levels as a source of nutrients for the fungi (Kasper et al 2005).

However, it is also possible that changes to the mucosal immune response affect the ability of *Candida* to colonise the oral mucosa. It has been shown that buccal epithelial cells from diabetic patients permit increased adhesion of *C. albicans*. The mechanism of this binding is unknown but may be due to reduced salivary lysozyme production of extracellular proteinases or up regulation of receptors for complement such as inactivated C3b (iC3b) in high glucose concentrations. Alternative theories include increased adhesion of *C. albicans* to epithelial cells when grown in high sugar media due to the development of a fibrofloccular layer on yeast cell surfaces. Accumulation of glycosylation products in epithelial cells may increase numbers of receptors for *C. albicans*. In addition it has also been reported that high salivary glucose concentrations may lead to increased resistance to intracellular killing by macrophages (Manfredi et al 2006).

2.7 Candida Colonization of Oral Cavity

C. albicans may cause two major types of infection; superficial infections such as oral or vaginal infections and life-threatening systemic infections (Mayer et al 2013). In the oral cavity, *Candida* can adhere to the oral epithelial cells, saliva molecules and teeth. They also adhere to the inert polymers of dental prostheses and other oral microorganisms. In the mouth, *C. albicans* is primarily isolated from the posterior half of the dorsum of the tongue and secondarily from saliva and other sites of the oral cavity (Arendorf and Walker 1980).

2.8 Promoting Factor of Candidiasis

Clinically, there are some factors that predispose to oral candidiasis including drug therapy, especially broad-spectrum antibiotics, immuno modulatory and xerogenic medications, blood dyscrasias and malignancy, dietary factors, endocrine disorders, immunologic disorders and salivary changes (Farah et al 2000). Drug therapy, including broad-spectrum antibiotics, immuno modulatory medications and cytotoxic medications, alters the host susceptibility, resulting in oral candidiasis (Cannon et al 1995). Individuals with diabetes were found to have higher *Candida* carriage rate than the non-diabetics, presumably due to increased *Candida* growth with high glucose levels in saliva and decreased pH (Soysa et al 2005).

Local factors that promote oral candidiasis Local factors that predispose to oral candidiasis include irritation from ill-fitting dentures and poor oral hygiene (Farah et al 2000). Poor denture hygiene such as wearing the dentures continuously without taking them out at night and poor denture cleanliness predisposes the individuals to denture-related oral candidiasis.

2.9 Clinical Presentations of Oral Candidiasis

Clinically, oral candidiasis may present as pseudomembranous candidiasis, erythematous candidiasis, hyperplastic candidiasis, denture-associated

erythematous candidiasis, angular cheilitis, median rhomboid glossitis and chronic mucocutaneous candidiasis (Napenas et al 2009; Farah et al 2010).

2.9.1 Localized oral infections

There are 3 major types of infections caused by *Candida albicans*: Oropharyngeal candidiasis, vulvovaginal (genital) candidiasis, and invasive candidiasis (candidemia).

2.9.2 Oropharyngeal Candidiasis

Oropharyngeal candidiasis is an infection in the mouth and throat area. Usually, it is characterized by the formation of white patches on top of the tongue and throughout the mouth, which is also known as “thrush”. Thrush can be removed with a blade or a cotton-tipped swab, but the underlying tissue will be irritable and show a distinct redness. This infected area will cause soreness and difficulty during eating (Robertson 2011).



Oropharyngeal Candidiasis: (https://en.wikipedia.org/wiki/Oral_candidiasis)

2.9.3 Vulvovaginal (genital) candidiasis

Vulvovaginal candidiasis is the infection of the genital region, typically the vaginal walls, in women. The vaginal yeast infection causes itchiness and a burning-sensation in the vagina and surrounding tissues. Also, a white discharge – described with an appearance similar to white cottage cheese – is typically present. Genital candidiasis is much more prevalent in women, but men can also contract it. Although it is not considered an STD, men are usually infected after sex with a woman having a vaginal yeast infection. Symptoms involved rash, irritation on the head and surrounding skin of the penis (Robertson 2011).

2.9.4 Invasive Candidiasis (Candidemia)

Invasive candidiasis (or candidemia) is the infection of *C. albicans* into the bloodstream. This leads to its invasion of organs throughout the body, such as the kidney, liver, brain, and many more. Patients began to suffer from fevers, chills, fatigue, muscles aches, and abdominal pains. Typically, patients with compromised immune systems are only at risk, while healthy people are susceptible to oral/genital candidiasis. Compromised immune systems can be caused by chemotherapy, transplantation, broad-spectrum antibiotics, and much more (Robertson 2011).

2.10 Mechanism of Resistance

Resistance to imidazoles and triazoles, particularly fluconazole, is more common than to polyenes, allylamines and echinocandins (Cannon et al 2009). Host factors that predispose to azole resistance are immunocompromised, including HIV infection or in bone marrow transplant patients undergoing immunosuppressive therapy and repeated or long term use of azole antifungals. There are multiple mechanisms of azole resistance in *C. albicans* including mutations in the gene ERG11 involved in ergosterol biosynthesis and the overexpression of drug efflux pumps (White et al 2002). ATP-binding cassette (ABC) pumps and the major facilitator superfamily (MFS) transporters are the two main families of the efflux protein. Azoles target the 14 α -demethylase enzyme encoded by ERG11, blocking

ergosterol biosynthesis. This leads to depletion of ergosterol, thus inducing the accumulation of intermediates from the toxic sterol pathways, which inhibit growth (Ramage et al 2012). High-level azole resistance is caused by the overexpression of ABC efflux pumps in the plasma membrane (Cannon et al 2009). The overexpression of these transporters plays a major role in developing antifungal drug resistance, mainly to azoles (Akins 2005) by reducing the intracellular azole concentration. Interestingly, expression of these ABC efflux pumps is induced in *C. albicans* cells by the antipsychotic fluphenazine.

Another important factor in azole resistance is biofilm production on host tissues by *C. albicans* (Cannon et al 2009). These biofilms are resistant to azole antifungal agents. Biofilms are defined as an enclosed extracellular matrix (ECM) containing highly structured communities of microorganisms, either attached to the surface or attached to one another (Ramage et al 2012). Microorganisms that produce biofilms have advantages such as protection from the environment, resistance of physical and chemical stress, metabolic cooperation and community-based regulation of gene expression.

2.11 Prevalence of *Candida* in the Community

Candida albicans is normal flora, lives in 40- 80% of the human population with no harmful effects, it recognizes and destroys harmful bacteria. In a healthy person, it is found in low concentrations and is controlled by immune system and the beneficial (probiotics) bacteria such as Lactobacilli.

2.12 Sources and transmission of *Candida*

Transmission

Candida albicans is usually transmitted from mother to infant through childbirth, and remains as part of a normal human's microflora. The typical reservoir for *C. albicans* is in the normal human microflora, and is not found in animal vectors. People-to-people acquired infections mostly happen in hospital settings where

immunocompromised patients acquire the yeast from healthcare workers; studies show about a 40% incident rate (Robertson et al 2011).

2.13 Clinical presentations

Pseudomembranous candidiasis Pseudomembranous candidiasis or thrush is the most common presentation of oral candidiasis (Cannon et al 1995). It presents clinically as confluent whitish-yellow creamy or yellow velvety plaques on the surfaces of the oral mucosa (Reichart et al 2000; Farah et al 2010).

2.13.1 Erythematous candidiasis: The clinical presentation of erythematous candidiasis (previously known as atrophic candidiasis) is localized erythema of the oral mucosa (Reichart et al 2000).

2.13.2 Hyperplastic candidiasis: Hyperplastic candidiasis presents as a chronic, well-demarcated, slightly raised, adherent white lesion of the oral mucosa. It ranges from small, translucent lesions to large, dense opaque, hard and rough on palpation, plaque-like lesions (Scully et al 1994).

2.13.3 Denture-associated erythematous candidiasis: A common inflammatory oral mucosal lesion that appears on the mucosa in contact with the fitting surface of a denture. It is frequently asymptomatic, but patients may experience slight soreness or a burning sensation (Scully et al 1994).

2.13.4 Angular cheilitis: Clinically, it appears as erythematous, fissured lesions at the corners of the mouth, usually asymptomatic and bilateral (Samaranayake et al 2002; Farah et al 2010).

2.14 Action of Antifungal Drugs

2.14.1 Polyenes

Polyenes are Macrolide antibiotics, containing unsaturated diene bond. The polyene antibiotics are all products of *Streptomyces* species. These antibiotics interact with sterols in cell membranes (ergosterol in fungal cells; cholesterol in

human cells) causing increased membranes permeability with subsequent leakage of intracellular ions and materials and death of the cell. Second, it causes oxidative damage of cytoplasmic membrane components and release of lethal free radicals. The polyene antifungal agents include nystatin, amphotericin B, and pimarinic.

.14.2 Azoles

Azole medications are a family of antifungal drugs that end in the suffix "-azole". An azole is a class of five-member nitrogen heterocyclic ring compounds containing at least one other non-carbon atom of either nitrogen, sulfur, or oxygen (Eicher and Hauptmann 2003). The clinically useful imidazoles are clotrimazole, miconazole, and ketoconazole. Two important triazoles are itraconazole and fluconazole. Clotrimazole and Itraconazole are insoluble in water; Ketoconazole is soluble at pH 3 or less. Fluconazole is water soluble at neutral pH (Johnson and Kauffman 2003).

Azoles have a broad antifungal spectrum in vitro, activity has demonstrable in experimental animals or patients with candidiasis. The azole inhibits cytochrome P450-dependent enzymes (particularly C14-demethylase) involved in the biosynthesis of ergosterol, which is required for fungal cell membrane structure and function the azoles are being used for muco-cutaneous candidiasis, dermatophytosis, and for some systemic fungal infections (Salvo 2009).

2.15 Resistance

2.15.1 Biofilm

In *C. albicans*, the biofilm matrix is largely composed of polysaccharides such as β -1,3-glucan, β -1,6-glucan, and mannans and to a lesser extent, proteins (Al-Fattani and Douglas 2006). A biofilm is a microbially derived sessile community characterized by cells that are irreversibly attached to a substratum or interface or to each other, embedded in a matrix of extracellular polymeric substances that they have produced, and exhibiting an altered phenotype with respect to growth rate and gene transcription. The biofilm and the formation of an extracellular

matrix, results the difficulty for the antifungal agents to reach yeast cells and shields from environment. The main antifungal mechanism is mediated by efflux pump and presences of subpopulation of perister cells are known (Douglas 2003; Ramage et al 2006).The studies indicated that the Antifungal drug resistance develops with the Biofilm maturation (Chandra et al 2001).

2.15.2 Mechanisms of *Candida albicans* resistance to antibiotics

Candida albicans strains are typically susceptible to fluconazole and certain other azole antifungals, but there are increasing reports of resistance, especially in HIV patients. Several mechanisms have been reported:

1. Reduced membrane ergosterol due to defective biosynthetic genes.
2. Alterations in sterol content or structure.
3. Masking of ergosterol molecules (Fidel et al 1999; Cooper 2007).

2.16 Host Immune Response

Candida albicans possess the ability of evading the host immune system immune system's immunological surveillance. Studies have shown that the innate and adaptive immune systems play a role in the clearing of fungal growth. T Helper I cells are known to produce cytokines that activate phagocytes (Romani 2000).

2.17 Prevention and Treatment

Taking the following measures can help reduce the risk of oral thrush developing (Robertson 2011):

- Brushing regularly: Teeth must be brushed twice a day with toothpaste containing fluoride.
- Cleaning dentures: Dentures should be cleaned every day.

- Attending dental appointments regularly: Dental check-ups should be attended regularly. Diabetes patients must attend dental appointments regularly.
- Keeping diabetes under control: Individuals with diabetes should therefore keep their blood sugar level under control, to reduce the amount of sugar in their saliva.
- Taking care what you eat: Sugar enriched foods can favor the growth of yeast. Gutkha and Betel Quid must be avoided.
- Rinsing the mouth after corticosteroid inhalation: People who use a corticosteroid inhaler for asthma should rinse their mouth and brush their teeth afterwards.
- Stopping smoking: Inhaled tobacco smoke dries the mouth and disrupts the microbial balance which can lead to overgrowth of *Candida*.

Antifungal Agents: (<https://www.cps.ca/en/documents/position/antifungal-agents-fungal-infections>)

- Oral candidiasis:** Nystatin, miconazole, amphotericin B.
- Cutaneous candidiasis:** Clotrimazole, econazole, ciclopirox, miconazole, ketoconazole, nystatin.
- Systemic and oral azoles:** Fluconazole, itraconazole or posaconazole.
- Vulvovaginitis:** single dose of oral fluconazole, topical antifungals (butoconazole, clotrimazole, miconazole, nystatin, ticonazole, terconazole).
- Blood infections:** intravenous fluconazole or an echinocandin (caspofungin)
- Candidemia:** Fluconazole and Anidulafungin

CHAPTER III

MATERIALS AND METHODS

3.1 Materials

A complete list of materials, equipment's, chemicals, reagent, antibiotics and media used for this study are listed in Appendix I.

3.2 Methods

3.2.1 Place of study

The study was carried out in Dharan Sub Metropolitan city, Eastern Nepal from May to September 2018.

3.2.2 Sample size and types

During the study 200 oral rinse samples were analyzed. All the work concerning this research was carried out in microbiology laboratory in Central Campus of Technology. The different clinical samples analyzed were from different potential risk population (50-barbers, 50-municipal waste workers, 50-diabetic and 50-healthy individuals).

3.3 Sample collection

The clinical sample for study were collected randomly from the sample population and transported to microbiology laboratory maintaining cold chain (CDC guideline D). All the collected samples were labeled with participant's identification number. In case of delay, the sample was usually stored at 4°C in the refrigerator. The sample from diabetic patients will be collected on basis of inclusion and exclusion criteria.

3.3.1 Inclusion criteria

Group I patients: In the inclusion criteria, participant having DM without any other oral lesions with following criteria were included in the study. Participants who have not received antibiotic and corticosteroid therapy before 4 weeks were included in study.

1. Random blood sugar (RBS) ≥ 200 mg/dl or
2. Fasting blood sugar (FBS) > 126 mg/dl.
3. Group II patients: Patients who did not have DM or any other systemic illness was included in the Group 2 (Control group).

Group 2: It included Healthy population who were nutritionally fit, without any clinical signs of diseases, without any clinical medication.

3.3.2 Exclusion criteria

The people who never meet above criteria were included under exclusion criteria.

3.4 Culture of oral rinse in SDA

Ten ml of sterile saline were allowed to be rinsed for 1 minute and inoculated in a broader capped sterile container .An aliquot of 50 microliter were inoculated in SDA (HiMedia, Mumbai, India) with chloramphenicol (0.05 g/l) and incubated at 37°C for 24-48 hours (Lamichhane et al 2015). Pure culture was identified by colony characteristics, grams staining and biochemical tests. The culture sample was subjected for antifungal susceptibility test, biofilm production and virulence activity.

3.5 Assessment of *Candida* colonization by Quantitative Enumeration of *Candida*.

Number of colonies formed after incubation were counted by colony counter counted and multiplied with a factor of 20 to get the colonies in 1 ml of a subject's sample.

Number of colonies contained in 50 μ l of sample = n

Therefore the number of colonies in 1000 μ l

(1 ml)

= n x 1000/50

= n x 20

3.6 Identification of Isolates

3.6.1 Identification with staining method

Gram staining was performed as according to standard technique using acid alcohol as decolorizer. Staining procedure and reagents are given in appendices.

3.6.2 Identification with biochemical test

Appropriate biochemical test were performed for identification of yeast isolates:

- i. Germ tube test
- ii. Chlamyospore formation test

The procedures for germ tube of *Candida albicans* are mentioned in the Appendix. *Candida albicans* was identified by Chlamyospore formation on Corn meal agar.

3.7 Characterization

The Biofilm production, Antifungal susceptibility test, phospholipase test and Haemolysin activity, Haemolysis Degree was studied.

3.7.1 Hemolysin Assay

Haemolysin activity was evaluated according to Manns et al (1994). Hemolysin production by *Candida albicans* was performed by inoculation overnight culture of yeast on Sugar-enriched sheep blood agar as described by Manns et al (1994). The Blood base agar media was prepared by adding 5-7 ml of fresh blood to Saboured Glucose Agar with 3% glucose. The plates were incubated at 37°C in 5% CO₂ for 48 hrs. The ratio of diameter of colony to the sum of diameter of the colony and the zone gives Hemolytic Index (Hz value).

3.7.2 Screening impact of diabetes in hemolytic activity

The hemolytic activities were tested on Saboured dextrose Broth liquid media (SDB) containing 7% defibrinated human blood according to Malcok et al (2009). One was supplemented with 3% glucose and the other without glucose. *Candida albicans* culture was inoculated and incubated for 48 hrs. The hemolysis in the media was detected spectrophotometrically by measuring the amount of released hemoglobin and compared with a standard hemolysate which was prepared prior to testing. The degree of hemolysis (percentage value) by an individual strain was calculated according to the following formula below: (Absorbance of supernatant media at 540 nm/Absorbance of standard hemolysate at 540 nm X 100).

3.7.3 Screening *Candida albicans* for production of phospholipase

The phospholipase test was done according to Samranayakae et al (1984). Egg yolk agar media was inoculated by 2 µL of the inoculum and allowed to dry at room temperature. The plates will be incubated at 37°C for 3-4 days. Pz will be

measured by dividing the diameter of the colony by the sum of diameter of the colony and the zone.

3.8 Biofilm Assays

3.8.1 Microtitre plate method

The quantification of biofilm was performed according to Christensen et al (1985). In this method, 5 ml of overnight culture of *Candida albicans* was prepared. Then 100 microliter of diluted culture was inoculated in a microtitre well containing TSB with glucose. The plate was incubated at 37°C for 24 hours for biofilm production. The unbound cell was discarded and washes several times. 125 µl of 0.1 % crystal-violet solution was added and left for 10-15 mins incubation. The plate was washed and left inverted for dry. The quantitative Determination was performed by solubilizing the biofilm by adding 125 µl of 30% acetic acid to each well and incubated the plate for 10-15 mins at room temperature and transfer to another microtitre plates and reading the absorbance at 405 nm by ELISA plate Reader. Interpretation is made on OD by subtracting OD of control wells from OD of test wells.

Mean OD	Adherence	Biofilm formation
<0.120	Non/Weak	Non/Weak
0.120-0.240	Moderate	Moderate
>0.240	Strong	Strong

3.8.2 Tube method

A qualitative assessment of biofilm formation was done as described by Christensen et al (1985). The TSB glu (10 mL) was inoculated with a loop full of *Candida albicans* from overnight culture plates and incubated for 24 hours at 37°C. The tubes was decanted and washed with PBS (pH 7.2) and dried. Then the tubes were stained by 0.1% crystal violet. Stain was removed by deionized water.

Tubes were then dried in inverted position for biofilm formation. Biofilm formation was considered positive when a visible film lined the wall and bottom of the tube. Ring formation at the liquid interface was not indicative of biofilm formation. Experiments were performed in triplicate and repeated for three times.

3.8.3 Congo red Agar Method (CRA)

The *Candida albicans* culture was streaked on surface of Congo Red Agar and incubated at 37°C for 24-48 hours (Freeman et al 1989). Black coloured colonies with dry crystalline consistency interpreted as positive biofilm producing strains. Red coloured colonies- interpreted as negative for biofilm production.

3.9 Antifungal Susceptibility Testing

All *Candida albicans* isolated from samples were subjected to in-vitro antifungal susceptibility test by Kirby-Bauer disc diffusion method as recommended by CLSI 2010. In this study the antifungals used were Amphotericin-B (100 Units) and fluconazole 10 (mcg) (Himedia, Mumbai India).

3.10 Quality Control for Tests

In this study, quality and accuracy of all tests was maintained by following standard procedures of collection, isolation and identification. For quality control, media, antibiotics and reagents were prepared, stored and utilized as recommended by the manufacturing company. Antifungal discs were stored at refrigerator temperature.

3.11 Data Analysis

The information collected from questionnaire was documented and tabulated. The data were statistically analyzed at 5 % level of significance by SPSS.

CHAPTER IV

RESULTS

The study was done in Microbiology Lab of Central Campus of Technology; study period was from 23rd June to September 26, 2018.

4.1 Gender wise Distribution of *C. albicans* in sample population

Candida albicans were isolated from 29 (69.04%) male population and 13 (30.96%) female population.




Figure 4.1: Gender wise distribution of *C. albicans* in sample population

4.2 Age wise Distribution of *C. albicans* in sample population

In this study, total *Candida albicans* isolated was 42 out of 63 positive samples of total *Candida*. The maximum frequency of organism was found in between age group of 40-50 years. The association of *Candida* in in different age groups was found to be statically insignificant $p= 0.077$ ($P>0.05$).




Figure 4.2: Age wise distribution of *Candida albicans* in sample population

4.3 Comparative study of *Candida* Carriage isolated from different populations

In this study, all oral rinse samples were cultured and the quantification of *Candida* carriage was done by enumerating CFU/ml. Higher prevalence of *Candida* was isolated from Diabetic populations. The highest percentage of *Candida* carriage was isolated from Diabetic 29 (58%), Followed by Barbers 15 (30 %), Municipal waste worker 6 (12 %) and Healthy 13 (26 %). The Comparative study of *Candida* carriage isolated from different population is shown in **Table 4.3**

Fungal Load per mL of Sample (CFU)	Population Type				Total
	Barber	Diabetic	Healthy	Municipal Waste Worker	
Below 400	5	-	4	5	14
400-800	10	5	8	1	24
800-1200	-	15	1	-	16
1200-1600	-	8	0	-	8
1600 above	-	1	0	-	1
Total	15	29	13	6	63

Table 4.3: Comparative study of *Candida* Carriage isolated from different populations

4.4 Comparative study of *Candida albicans* isolated from different populations

In this study, all the oral rinse samples were cultured culture for growth of *Candida albicans*. Higher number of *Candida albicans* were isolated from Diabetic population 29 followed by Barbers 15, Municipal Waste worker 6 and Healthy populations 13 respectively. The highest percentage of *Candida albicans* was isolated from Diabetic population 16 (55.17%), followed by Barbers 15 (100%), Healthy population 6 (46.15%) and Municipal waste worker 5 (83.33%). The Comparative study of *Candida albicans* isolated from different Populations is shown in **Table 4.4**

Table 4.4: Comparative study of *Candida albicans* isolated from different Populations

Population	No of positive isolates	No of <i>Candida albicans</i>
1. Diabetic population	58% (29/50)	32% (16/50)
2. Barbers	30% (15/50)	30% (15/50)
3. Municipal waste workers	12% (6/50)	10% (5/50)
4. Healthy	26% (13/50)	12% (6/50)
Total	63	21% (42/50)

4.5 Prevalence of *Candida* in Population

The overall presence of *Candida* was 31.5 % whereas the overall prevalence of *Candida albicans* was 21 % in total 200 populations. The prevalence of *Candida* in population is shown in **Figure 4.5**.




Figure 4.5: Prevalence of *Candida* in Population

4.6 Antifungal susceptibility pattern of *Candida albicans* isolates:

It was found that 76.19 % (32/42) were Fluconazole resistant. Other antifungal agent was used to identify the susceptibility and resistant pattern of positive isolates and it was found that 50 % (21/42) were Amphotericin Resistant. The antifungal susceptibility test of *Candida albicans* is shown in **Table 4.6**

Table 4.6: Antifungal Susceptibility Test of isolated *Candida albicans*

Antifungal Agents	Total <i>Candida albicans</i>	Sensitive		Resistance		p value
		Number	Percentage	Number	Percentage	
Fluconazole (10mcg)	42	10	23.80 %	32	76.19 %	0.044
Amphotericin B (100 units)	42	21	50%	21	50%	

4.7 Phospholipase and Haemolysin assay

The Pz value of isolated *Candida albicans* ranged from 2 to 2.95 for all the isolates and 2.01 to 2.6 for isolates from Diabetic group and 2.09 To 2.89 for control groups. The mean Pz value in Diabetic population was 2.11 and in Control groups was 2.52. The P_Z Values of isolates are shown in **Table 4.7**. The Hz values ranged from 5 to 18 for Diabetic groups and 3.45 to 16 for Control Groups. The mean HZ value in Diabetic group was 9.28 and in Healthy controls were 7.91. The Haemolysis degrees of isolates are shown in **Table 4.7.1**

Table 4.7: Hemolysis and Phospholipase Index of *Candida albicans*

Activity	Diabetic (n=16)	Non-Diabetic (n=6)	Test	p value
Haemolysin Assay(mean)	9.28	7.91	T	0.049
Phospholipase Activity (mean)	2.09	2.52	t	0.89

Table 4.7.1: Hemolysis Degree exhibited by isolated *Candida albicans*

	Haemolysis Degree with Glucose	Haemolysis Degree without Glucose	p value
<i>C. albicans</i>	58.68 %	48.74 %	0.046

4.8 Biofilm assay by microtitre plate method

The 96-well microtitre plate method for biofilm formation was carried out. The overall biofilm producers were 69.04 % and 35.96 % were non biofilm producer. The strong biofilm producer was 2 (4.76 %), moderate biofilm producer was 27 (64.28%) and Weak/none biofilm producer were 13 (30.96%).

Table 4.8: Biofilm assay by microtitre plate method

Biofilm formation	No. of biofilm producing <i>Candida albicans</i> isolates	% of biofilm former <i>C. albicans</i>
High	2	4.75
Moderate	27	64.2
Weak/none	13	30.9
Total	42	100

4.9 Comparative study of Biofilm Assays

The comparative analysis of Biofilm formation of isolated *Candida albicans* was analysed by three methods; Microtitre plate method, Tube method and Congo Red Agar method which is shown in **Table 8**

Table 4.9: Biofilm formation by *Candida albicans* by three methods

Biofilm formation	Microtitre plate method	Tube method	Congo Red Agar method	p-value
High	2 (4.76%)	2 (4.76%)	1 (2.38%)	
Moderate	27 (64.28%)	16 (38.09%)	15 (35.71%)	0.049
Weak/None	13 (30.95%)	24 (57.14%)	26 (61.90%)	
Total isolates	42	42	42	

4.10 Comparative study of biofilm formation and antifungal drug resistance

The biofilm producing and antifungal drug resistance pattern of isolated *Candida albicans* is shown in (Table 4.10. 4.10.1 and 4.10.2).

Table 4.10: Comparative analyses of biofilm formation and drug resistance

Biofilm Formation	Biofilm forming <i>C. albicans</i> (%)	Antifungal Drug Resistance		p-value
		Flu	Amp	
Strong	2 (4.7%)	2	2	0.038
Moderate	27 (64.2%)	17	12	
Weak/None	13 (30.9%)	13	7	
Total	42 (100%)	32	21	

Table 4.10.1: Comparative analysis of biofilm and amphotericin B resistance

Fluconazole Drug	Biofilm Producer	Non Biofilm Producer	Total
Resistant	19	13	32
Sensitive	2	8	10
Total	21	21	42

Table 4.10.2: Comparative analysis of biofilm and fluconazole resistance

Amphotericin B Drug	Biofilm Producer	Non Biofilm Producer	Total
Resistant	13	8	21
Sensitive	8	13	21
Total	21	21	42




Figure 4.10.1: Biofilm formation and Amphotericin B drug resistance




Figure 4.10.2: Biofilm formation and Fluconazole drug resistance

4.11 Sensitivity and Specificity of Biofilm Screening Methods

The microtitre plate method was found to be most efficient standard method for studying biofilm formation as compared to tube method and Congo red agar method. The parameters like sensitivity, specificity, negative predictive value, positive predictive value and accuracy were calculated.

Table 11: Sensitivity and specificity of biofilm screening methods

Biofilm Screening Method	Sensitivity (%)	Specificity (%)	Positive predictive value (%)	Negative predictive value (%)	Accuracy (%)
Tube method	71.4	62.85	27.77	91.66	64.28
Congo Red Agar method	27.77	16.66	20	23	21.42

CHAPTER-V

DISCUSSIONS

Candida is a fungus that belongs to normal flora of oral cavity which is pathogenic under certain conditions. It can be a cause of opportunistic infections when host immune system is impaired (Jayachandran et al 2016). Diabetes mellitus is endocrine metabolic disorder in which Insulin secreted fails to metabolize blood glucose. *Candida albicans* is known to be carried out in oral cavity of 50 % of world's population as a part of normal flora. There is higher prevalence of *Candida* carriage in oral cavity of Diabetic patients when compared with non-diabetic population (Lamichhanea et al 2015).

Around 85-90 % of diabetic patients are diagnosed by Type-2 Diabetes. In Diabetic patients the salivary dysfunction such as Xerostomia, tooth decay, decreased salivary flow and periodontal diseases are common (Ship et al 2003). Diabetic patients are more susceptible to oral Candidiasis due to increased salivary glucose, low secretion of saliva, impaired chemotaxis and defect of phagocytosis (Kedar et al 2002). Many Risk factors are associated with colonization by *Candida*. Poor oral hygiene, diabetic conditions, immunosuppressive therapy in Cancer disease, intake of *Gutkha* has shown increasing prevalence of *Candida* species (Guggenheimer et al 2000).

The present Study was carried out at Microbiology and Molecular Biology Laboratory of Central Campus of Technology, Dharan. During the study period a total of 200 oral rinse samples were collected from three potentially risk populations (50 barbers, 50 municipal waste workers, 50 diabetic populations) and 50 healthy populations (Control). In the present study the overall prevalence of *Candida* species in sample population was 31.5% (63/200) and the prevalence of *Candida albicans* was 21% (42/200). In this study, *Candida albicans* were isolated from 29 (69.04%) male population and 13 (30.96%) female population.

Majima et al (2014) reported 17.8% oral candida carriage in male and 18.8% oral *Candida* carriage in female. Javed et al 2009 reported greater prevalence of *C. albicans* in oral cavity of denture wearing males (74%) than in female (23%) with diabetic mellitus Type II disease. Loster (2016) reported **that the infection free individual were greater in male than in female** and statistically significant relationship between intensity of yeast and gender.

The maximum frequency of organism was found in between age group of 40-50 years. The association of *Candida* in in different age groups was found to be statically insignificant $p= 0.077$ ($P>0.05$). Lockhart et al 1999 found the increase in oral candida carriage was reported by with age possibly due to diminished natural defenses. In our study the prevalence of yeast in elderly age group was found to be least possibly due to least sample population from old age group. There was no significant association between Age and prevalence of *Candida albicans*.

This study reported 31.5 % prevalence of oral *Candida*. Out of 63 positive Samples of *Candida*, 42 isolates were known to be *Candida albicans*. Statistically significant increase in Candida carriage in terms of colony forming units were reported in patients with Diabetes mellitus than in control Groups, $p<0.001$ with CFU/ml ranging from 0 to 1700. This result is similar too many other studies that explain the higher susceptibility of *Candida* to colonize oral cavity of diabetic patients. The study conducted by Lamichhane et al (2015) showed significant increase in Candida CFU in Diabetic patients than in Controls. Host factors which contribute to oral Candidal carriage in Diabetes are known to be Candidacidal activity of neutrophils in presence of Glucose. In diabetic patients with Candidiasis the Polymorphonuclear leucocytes (PMN) produces less free oxygen radicals exhibiting reduced phagocytosis, bactericidal activity and chemotaxis. This may confer Diabetic patients more susceptible to Oral Candida infections (Soysa et al 2005). Mohammadi F et al 2016 found 55% Diabetic patient to carry *Candida* sp. in oral cavity which *C. albicans* was abundant species. Belazi et al

(2005) isolated candida sp. from oral cavity of 64% diabetic and 40% control population.

Many researchers conducted throughout the world have reported cases of oral candidiasis in diabetic patients commonly known as oral thrush (Obradovic et al 2011). Pathogenic microorganisms are capable of acquiring iron for survival and establish infection in host that addresses its pathogenicity. Since there is little iron human body, the most microorganisms derive iron from hemoglobin. So to destroy hemoglobin, they secrete enzyme like haemolysin (Malcok et al 2009).

The mean hemolytic degree of *Candida albicans* in human blood with Glucose (SDBwG) was 58.68% and in human blood without glucose (SDBwoG) was 48.74%. We reported that *Candida albicans* exhibited higher hemolytic degree. Malcok et al (2009) reported in his study that most species of *Candida* exhibited hemolytic activity in 3% glucose enriched medium and hence suggested the parallel combination of Diabetic condition with pathogenesis of *Candida albicans*. In-vitro analysis of hemolytic degree of *Candida albicans* in presence and absence of glucose level strongly explains the increased blood sugar level increases the Hemolysin activity of *Candida albicans*. This study suggests the pathogenic role of *Candida albicans* in Diabetic mellitus and supports the concept of susceptibility of *Candida* colonization and Candidiasis in Diabetic patients. The Haemolysin Index of *Candida albicans* isolated from Diabetic patients was found higher than in Control population.

The Pz value of isolated *Candida albicans* ranged from 2.01 to 2.6 for isolates from Diabetic group and 2.09 To 2.89 for control groups. The mean Pz value in Diabetic population was 2.11 and in Control groups were 2.52. There was no significant difference in phospholipase activity in Diabetic and control groups (p=0.89). Tsang et al (2007) reported no significant difference among phospholipase activity among *Candida albicans* isolated from Diabetic and Control groups. Tsang et al (2007) reported higher proteinase and haemolytic

activity from Diabetic patients with no significant difference in phospholipase activity from test and control groups. Sachin et al (2012) reported 94.8% *C. albicans* exhibiting higher haemolysin activity and 92.3% exhibiting phospholipase activity. In our study all strains of *C. albicans* exhibited haemolysin activity and only 68% *C. albicans* exhibited phospholipase activity. In our study there was significant difference in Hemolysin activity among Diabetic and control groups ($p=0.049$).

Candida has known to be opportunistic pathogen under immunosuppression and tobacco chewing conditions (Javed et al 2014; Hsia et al 1981). It is suggested that individuals chewing Gutkha are susceptible to oral *Candida* infections than non-chewers (Abduljabbar et al 2017). Chewing Tobacco that includes Gutkha, Betel quid (BQ) which is common habit in South Asian nations like in India, Pakistan, Bangladesh, Sri Lanka and Nepal (Javed et al 2010). Betel quid is mixture of areca-nut, lime enveloped in piper betel leaf whereas Gutkha is found in Sachet (Javed et al 2013). The possible Explanation for greater *Candida* colonization in Gutkha consumers could be due to the presence of nicotine and hydrocarbons such as polycyclic aromatic hydrocarbons acting as nutrient for Oral yeast facilitating its growth (Abduljabbar, Hussain et al 2017; Hsia et al 1981). In our study, higher prevalence of *Candida* carriage was found in Gutkha chewers. The *Candida* colonization and Gutkha consumption was statistically significant $p=0.041$. Similar study by Abduljabbar et al (2017) reported a significant difference in Oral candida carriage in Gutkha chewer and Betel Quid chewer suggesting the susceptibility to oral candidiasis in those risk groups than in control groups. However Javed et al (2014) showed no significant difference in oral *Candida* colonization among Gutkha and Betel quid chewer. This contradiction in our study could be due to fact that Oral rinse sample were obtained for complete enumeration of *Candida* from oral cavity. The prevalence of oral *Candida* carriage in healthy population having good oral hygiene was low as compared to others. The healthy populations included individuals without physical complications and diseases, proper BMI, and no smoking, chewing and

Drinking Habit. The lower frequency of *Candida* carriage in healthy might be due to maintenance good oral hygiene and practice. We can at least explain that being a part of normal flora the colonization of *Candida* is associated even with poor oral hygiene.

All isolated strains of *Candida albicans* were tested for antifungal susceptibility testing by using Kirby Bauer disk diffusion method 76.19% were found to be Resistant to Fluconazole and 50% were found to be resistant to Amphotericin B. It was observed that emergence of drug resistance in *Candida albicans* is a major global issue which persuade for new search of therapeutic agents for eradicating the infections. The emerging Drug Resistance is has become global burden for treating the infections. *Candida* infection has been increasing in immunocompromised, over aged, patients receiving cancer chemotherapy and organ transplantation.

Biofilm formation mechanisms render difficulty in eradication by restriction to penetration by Drugs (Khatri et al 2015). In our study the maximum frequency of *Candida albicans* were biofilm producers and even maximum biofilm producing *Candida albicans* were resistant to antifungal drugs. This association may explain the ability of biofilm production with drug resistance in the organism exhibiting its strong virulence factor and making failure of antifungal drugs. In our study the antifungal resistance pattern of *Candida albicans* showed highest Resistance to fluconazole whereas Amphotericin B also showed good sensitivity. **Biofilm formation and overgrowth of *Candida* is found more in diabetic patients (Mohammadi et al 2016).**

The biofilm formation and Fluconazole resistance was statistically significant $p=0.03$ whereas the biofilm formation and Amphotericin B drug resistance was not significant. Amphotericin B showed a greater Sensitivity towards *Candida albicans*. Weak biofilm producing *Candida albicans* isolates showing resistance towards Amphotericin B could be due to efflux pump other than biofilm. Most

studies suggest that Amphotericin B displays a good activity against *Candida* biofilms. According to study conducted by Mahmoudabadi, Zarrin et al (2014) the 100% isolates of *Candida albicans* were biofilm producers where 65% showed Sensitivity towards Amphotericin B and only 26.7% Sensitivity towards Fluconazole. Similar findings were observed even in our study.

Biofilm helps candida to escape host defense and develop resistance to antimicrobial agents. Over last two decades the burden of *Candida* infection throughout the world has been rising with drug resistance. Diabetes mellitus patients, immuno-compromised patients like HIV patients, antibiotic users, IV users, Gutkha consumers etc. are at risk to *Candida* infection. Biofilm of *Candida* is made up of layers of cells embedded in matrix of extracellular polymeric materials (Khatri et al 2015). Biofilm is the surface-attached microbial community that contributes virulence factor. In our study 4.7% of isolated *Candida albicans* were strong biofilm producers, 64.2% were moderate and 30.9% were weak or non-biofilm producer. In overall the biofilm forming *Candida albicans* were 69% and non-biofilm producers were 30.9%.

In our study the strong, moderate and weak biofilm producers by microtitre plate method were 4.7%, 64.2% and 30.9% respectively. The strong, moderate and weak biofilm producers by TM method were 4.7%, 38% and 57.1% respectively. The strong, moderate and weak biofilm producers by CRA method were 2.3%, 35.7% and 61.9% respectively. Number of false positive and false negative was reported in the comparison. It was difficult to discriminate strong, moderate and weak biofilm producers in TM and CRA method due to phenotypic variations. Sensitivity and specificity of TM was found to be 71.4% and 62.8% respectively with accuracy of 64.2%. For Congo red agar method the sensitivity and specificity was found to be 27.7% and 16.6% with accuracy of 21.4%. The statistical analysis of screening were similar even in our findings which supports different other similar findings done before. Hassan et al (2011) concluded Microtitre method as gold standard technique for screening biofilm as compared to TM and

CRA. Even in our study The Microtitre method was considered efficient method for quantitative screening of Biofilm in comparison to TM and CRA methods.

In Nepal, improper use of antibiotics drugs without doctor's prescription, haphazard selling and buying of antibiotic from local pharmacy and unnecessary use of drugs have been responsible for drug resistance to microorganisms. This uncontrolled use of drug has led to antifungal drug resistance in strains of microorganisms. Indiscriminate use of drugs in our community is a major cause for emergence of drug resistance. The proper availability of microbiological investigation and information would be necessary in search of appropriate antimicrobial agents to fight with drug resistance. Since for many years Fluconazole has been used for treatment of oral candidiasis but the emergence of drug resistance renders the search of alternative antimicrobial therapy.

There was no statistical association between ages and prevalence of *Candida*. The good oral hygiene and the reduced prevalence of *Candida* carriage was statistically significant, $p=0.049$. In our study the total *Candida* carriage among Healthy Population was only 26 %. Majima et al (2014) found 18.3% oral *Candida* carriage among dental students and suggested that good oral hygiene responsible for elimination of *Candida*. Therefore with overall analysis in potential risk groups and in Healthy population, the oral *Candida* colonization shows a significant association with oral hygiene and serum glucose.

Higher prevalence of *Candida* in diabetic population and in poor oral condition alarms the oral health warnings. The absence of *Candida* in oral cavity may be due to maintenances of good oral health. Thus, oral carriage of *Candida* serves for health issues as oral candidiasis requires initial colonization by *Candida*.

CHAPTER-VI

CONCLUSION AND RECOMMENDATIONS

6.1 Conclusion

The highest prevalence of oral *Candida* was found to be in diabetic population and in Gutkha consumers. The greatest numbers of isolated *Candida albicans* were biofilm producer which showed greater frequency of Fluconazole drug resistance. Microtitre method was considered efficient method for screening biofilms. Higher prevalence of *Candida* in diabetic population and in poor oral condition alarms the oral health warnings. The absence of *Candida* in oral cavity may be due to maintenances of good oral health. Thus, oral carriage of *Candida* serves for health issues as oral candidiasis requires initial colonization by *Candida*. The maximum frequency of *Candida albicans* were biofilm producers and even maximum biofilm producing *Candida albicans* were resistant to antifungal drugs. This association may explain the ability of biofilm production with drug resistance in the organism exhibiting its strong virulence factor and making failure of antifungal drugs. In our study the antifungal resistance pattern of *Candida albicans* showed highest Resistance to fluconazole whereas Amphotericin B displays a good activity against *Candida* biofilms.

6.2 Recommendations

1. Since diabetic populations harbor higher frequency of *Candida* carriage, so they should control blood glucose level by adopting healthy lifestyle with good oral hygiene.
2. Unauthorized use and distributions of antibiotics must be controlled to prevent emerging drug resistance in microorganisms.
3. Intake of Gutkha, BQ must be abandoned and proper oral hygiene must be followed.
4. Microtitre method is gold standard for biofilm assay than the Tube method and congo red agar method.

References

- Abduljabbar T, Hussain M, Adnan T, Vohra F and Javed F (2017). "Comparison of oral Candida species prevalence and carriage among gutka-chewers and betel-quid chewers." *J Pak Med Assoc* ,67: 350-354.
- Abu-Elteen KH, Hamad MA, and Salah SA (2006). Prevalence of Oral Candida Infections in Diabetic Patients. *Bahrain Medical Bulletin*, 28(1), 1-8.
- Akins RA. (2005). An update on antifungal targets and mechanisms of resistance in *Candida albicans*. *Medical Mycology*, 43(4), 285–318. doi:10.1080/13693780500138971.
- Al-Fattani MA, Douglas LJ (2006). Biofilm matrix of *Candida albicans* and *Candida tropicalis*: chemical composition and role in drug resistance. *J Med Microbiol*, 55 999 -1008.
- Alzarea BK, Sghaireen MG, Taher I, Mohager M. (2015). Prevalence of Oral candidiasis in Diabetic patients at Northern of kingdom of Saudi Arabia. *Research journal of biological Sciences*, 10:10-14.
- Arendorf TM, & Walker DM (1980). The prevalence and intra-oral distribution of *Candida albicans* in man. *Archives of Oral Biology*, 25(1), 1–10.
- Barbeau J, Séguin J, Goulet JP, de Koninck L, Avon SL, Lalonde B, & Deslauriers N (2003). Reassessing the presence of *Candida albicans* in denturereLATED stomatitis. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology*, 95(1), 51-59.
- Bartholomew GA, Rodu B and Bell DS (1987). Oral Candidiasis in Patients with Diabetes Mellitus: A Thorough Analysis. *Diabetes care*, 10(5).

- Berman J, Sudbery PE (2002). *Candida Albicans*: a molecular revolution built on lessons from budding yeast. *Nat Rev Genet.* 3(9)18-30; PMID: 12459722; [http:// dx.doi.org/10.1038/nrg948](http://dx.doi.org/10.1038/nrg948).
- Brock M. (2009). Fungal metabolism in host niches. *Current Opinion in Microbiology.* 12(4):371-6.
- Brown V, Sexton JA and Johnston M (2006). A Glucose Sensor in *Candida albicans*. *Eukaryot. Cell.* 5; (10): 1726–1737.
- Blot SI, Vandewoude KH, Hoste EA, Colardyn FA (2002). Effects of nosocomial candidemia on outcomes of critically ill patients. *American Journal of Medicine.* 113(6):480-5.
- Buchan ADB, Kelly VA, Kinsman OS, Gooday GW & Gow NAR (1993). Effect of trifluoperazine on growth, morphogenesis and pathogenicity of *Candida albicans*. *Medical Mycology*, 31(6), 427-433.
- Budtz-Jorgensen E. (1990) Histopathology, immunology and serology of oral yeast infections, Diagnosis of oral candidosis. *Acta Odontol Scand* 48: 37-43.
- Cannon RD & Chaffin WL (1999). Oral Colonization By *Candida albicans*. *Critical Reviews in Oral Biology & Medicine*, 10(3), 359–383. doi: 10.1177/10454411990100030701.
- Centers for Disease Control and Prevention. Candidiasis. [<http://www.cdc.gov/fungal/diseases/candidiasis/index.html>].
- Chandra J, Kuhn, DM, Mukherjee PK, Hoyer LL, McCormick T and Ghannoum, MA (2001). Biofilm Formation by the Fungal Pathogen *Candida albicans*: Development, Architecture, and Drug Resistance. *Journal of bacteriology*, 183(18), 5385–5394.

- Christensen GD, Simpson WA, Younger JJ, Baddour LM, Barrett FF, Melton DM, Beachey EH (1985). Adherence of coagulase-negative Staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. *J Clin Microbiol.* 22(6):996-1006.
- Clinical and Laboratory Standards Institute (2010). Performance standards for antifungal disk diffusion susceptibility testing of non-dermatophyte filamentous fungi; Informational supplement-First edition. CLSI document M51-A. Villanova, PA: Clinical and Laboratory Standards Institute; Back to cited text no. 31.
- Cotter G, Kavanagh K. (2000). Adherence mechanisms of *Candida albicans*. *Br J Biomed Sci*; 57:241-9.
- Cullen, P. J. & Sprague, G. F., Jr (2012). The regulation of filamentous growth in yeast. *Genetics* 190, 23–49.
- Daniluk T, Tokajuk G, Stokowska W, Fiedoruk K, Sciepuk M, Zaremba ML, (2006). Occurance rate of oral *Candida albicans* in denture wearer patients. *Adv Med Sci* ; 51 Suppl 1: 77-80.
- Dean C. (2009). *Yeast and Inflammation*. Jigsaw Health, LLC.
- De-leon EM, Jacober, SJ, Sobel JD and Foxman B (2002). Prevalence and risk Factors for Vaginal *Candida* Colonization in women with type I and II diabetes. *BMC. Infect. Dis.*, 2:1-11.
- Demirezen S, Dirlik OO and Beksa MS (2005). The association of *Candida* infection with intrauterine contraceptive device. *Dep. of Bio. Ankara, Turkey*; 13; (1):32– 4 (Abstract).
- DeRepentigny L, Lewandowski D, Jolicoeur P (2004). Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. *Clinical Microbiology Review.* 17(4):729-59.

- Dorocka-Bobkowska B, Budtz-Jorgensen E, Wloch S (1996). Non-insulin-dependent diabetes mellitus as a risk factor for denture stomatitis. *J Oral Pathol Med.* 25:411–5.
- Douglas LJ (2003). Candida biofilms and their role in infection. *Trends in microbiology*, 11 (1), 30-36.
- Espinoza I, Rojas R, Aranda W, Gamonal J (2003). Prevalence of oral mucosal lesions in elderly people in Santiago, Chile. *J Oral Pathol Med*; 32(10): 571-5.
- Fanelloa S, Boucharab JP, Jousseta N, Delbosa V, LeFlohicc AM (2001). Nosocomial *Candida albicans* acquisition in a geriatric unit: epidemiology and evidence for person-to-person transmission. *Journal of Hospital Infection.* 47(1):46-52.
- Fanning S, Mitchell AP. (2012). Fungal biofilms. *PLoS Pathog*; 8:e1002585; PMID: 22496639;<http://dx.doi.org/10.1371/journal.ppat.1002585>
- Farah CS, Lynch, N, & McCullough MJ (2010). Oral fungal infections: an update for the general practitioner. *Australian Dental Journal*, 55 Suppl 1, 48–54. doi:10.1111/j.1834-7819.2010.01198.
- Fatahinia M, Poormohamadi F, Mahmoudabadi AZ (2015). Comparative Study of Esterase and Hemolytic Activities in Clinically Important *Candida* Species, Isolated From Oral Cavity of Diabetic and Non-diabetic Individuals. *Jundishapur J Microbiol*, 8(3): e20893.
- Fongsmut T, Deerochanawong C, Prachyabrude W (1989). Intraoral *Candida* in Thai diabetes patients. *J Med Assoc Thai* 1998; 81: 449-53.
- Freeman D J, Falkiner F R, Keane C T (1989). New method for detecting slime production by coagulase negative *Staphylococci*. *J Clin Pathol.* 1989 Aug; 42(8):872-4.

- Garber A. (1998). Diabetes mellitus. In: Stein JH, editor. Internal Medicine. 5th Ed. Vol. 1. St Louis: Mosby. pp. 1850–4.
- Ghannoum, M. A. (2000). Potential role of phospholipases in virulence and fungal pathogenesis. *Clin Microbiol Rev* 13, 122–143.
- Gow NAR & Hube B (2012). Importance of the *Candida albicans* cell wall during commensalism and infection. *Current Opinion in Microbiology*, 15(4), 406–412. doi:10.1016/j.mib.2012.04.005.
- Guggenheimer J, Moore PA, Rossie K (2000). Insulin dependent diabetes mellitus and oral soft tissue pathologies, II: prevalence and characteristics of *Candida* and candidal lesions. *OOOOE* 2000; 89:6- 570.
- Guggenheimer J, Moore PA, Rossie K, Myers D, Mongelluzzo MB, Block HM (2000). Insulindependent diabetes mellitus and oral soft tissue pathologies. II. Prevalence and characteristics of *Candida* and candidal lesions. *Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol*; 89(5):570-6.
- Hada DS, Thakur S, Hada P, Chaudhary A. (2016). Oral *Candida* carriage in Diabetic and Non-Diabetic patients receiving Hemodialysis. *International Journal of Oral Care and Research*, 4(3):189-195.
- Hadley and Mac E. (2000). *Endocrinology*. Prentice Hall. pp. 467.
- Hassan A, Usman J, Kaleem F, Omai M, Khalid A, Iqbal M (2011). Evaluation of different detection methods of biofilm formation in the clinical isolates. *Brazilian journal of infectious Diseases*, 15(4); 305-311.
- Hautala T. (2007). A cluster of *Candida krusei* infections in a haematological unit. *BMC Infectious Diseases*, 7:97.

- Hidalgo JA, Vazquez JA, Bronze MS (2014). Candidiasis: Frequency. [<http://emedicine.medscape.com/article/213853-overview#aw2aab6b2b3aa>].
- Hill LV, Tan MH, Pereira LH, Embil JA (1989). Association of oral candidiasis with diabetic control. *J Clin Pathol.*; 42:502–5.
- Hsia CC, Sun TT, Wang YY, Anderson LM, Armstrong D, Good RA (1981). Enhancement of formation of the esophageal carcinogen benzylnitrosamine from its precursors by *Candida albicans*. *Proc Natl Acad Sci USA.*; 78:1878-81.
- http://www.emedicinehealth.com/candidiasis_yeast_infection/page3_em.htm#candidiasis_yeast_infection_symptoms_and_signs.
- Jacobsen ID, Wilson D, Wächtler B, Brunke S, Naglik JR, Hube B (2012). *Candida albicans* dimorphism as a therapeutic target. *Expert Rev Anti Infect Ther*; 10:85- 93; PMID: 22149617; <http://dx.doi.org/10.1586/eri.11.152>.
- Jafari AA, Khanpayah E, Ahadian H.(2013) Comparison the Oral *Candida* Carriage in Type 2 Diabetic and Non Diabetics. *Jundishapur Journal of Microbiology*, 6(7): e8495.
- Javed F, Chotai M, Mehmood A, Almas K (2010). Oral mucosal disorders associated with habitual gutka usage: a review. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 109:857-64.
- Javed F, Tenenbaum HC, Nogueira-Filho G, Nooh N, Taiyeb Ali TB, Samaranayake LP. (2014). Oral *Candida* carriage and species prevalence amongst habitual gutka-chewers and non-chewers. *Int Wound J.* 11:79-84.
- Javed F, Yakob M, Ahmed HB, Al-Hezaimi K, Samaranayake LP. (2013). Comparison of oral *Candida* species prevalence and carriage among gutka-chewers and betel-quinid chewers 353 *Candida* carriage among individuals

chewing betel-quinid with and without tobacco. *Oral Surg Oral Med Oral Pathol Oral Radiol*; 116:427-32.

Jayachandran AL, R. Katragadda, R. Thyagarajan, L. Vajravelu, S. Manikesi, S. Kaliappan and B. Jayachandran (2016). "Oral Candidiasis among cancer patients attending a tertiary Care Hospital in Chennai, South India: an evaluation of Clinicomycological association and antifungal susceptibility pattern." *Canadian Journal of Infectious Diseases and Medical Microbiology*.

Joanne M. Manns David M. Mosser, and Helen R. Buckley (1994). Production of a Hemolytic Factor by *Candida albicans*, *Infection and Immunity*, Nov. 1994, p. 5154-5156 0019-9567/94/\$04.00+0 Copyright C, American Society for Microbiology, 62(11).

Kabir MA, Hussain MA, Ahmad Z (2012). *Candida albicans*: A Model Organism for Studying Fungal Pathogens. *ISRN Microbiology*. 2012: 538694.

Kadir T, Pisiriciler R, Akyüz S, Yarat A, Emekli N, Ipbüker A (2002). Mycological and cytological examination of oral candidal carriage in diabetic patients and nondiabetic control subjects: thorough analysis of local aetiologic and systemic factors. *J Oral Rehabil*. 29(5):452-7.

Kauffman, CA and Hedderwicks, S (1997). Opportunistic fungal infection: filamentous and cryptococcosis. *Geriatrics*, 52; (10):40-49.

Kayser FH, Bienz KA, Eckert J and Zinkernagel RM. (2005). *Medical Microbiology*. Thieme Stuttgart, New York. PP: 229-233, 348-374.

Kerawala C, Newlands C (editors). (2010). *Oral and maxillofacial surgery*. Oxford: Oxford University Press. pp. 446, 447. ISBN 9780199204830.

Khatri S, M. Sumana RP Mahale and A. Kishore. (2015). "Analysing three different screening methods for biofilm formation in clinical isolates of

Candida." *Journal of Evolution of Medical and Dental Sciences* 4(83): 14515-14524.

Khaled H, Mawieh A, Suleiman A. (2006). Prevalence of oral Candida infections in diabetic patients. *Bahrain Medical Bulletin*; 28(1).

Kuprowski, M. (1966). The influence of the quality of the agar on the occurrence of haemolysis in cultures of *Candida albicans*. *Zentralbl. Veterinaermed. Reihe B* 13:364-368.

Kurtzman CP and Piškur J. (2006). Taxonomy and phylogenetic diversity among the yeasts (in *Comparative Genomics: Using Fungi as Models*).

Lamichhane RS, Boaz K, Natarajan S, Shrestha M, (2015). Assessment of Candidal carriage in patients with Type II Diabetes Mellitus. *Journal of Pathology of Nepal*, Vol. 5, 733-738.

Lamont RJ, Burne RA, Lantz MS, Leblanc DJ. (2006). Fungi and fungal infections of the oral cavity. *American Society of Microbiology*, pp. 333–348.

Lindquist S. (1992). Heat-shock proteins and stress tolerance in microorganisms. *Curr Opin Genet Dev* 1992; 2:748-55; PMID: 1458023; [http://dx.doi.org/10.1016/S0959-437X\(05\)80135-2](http://dx.doi.org/10.1016/S0959-437X(05)80135-2).

Liu XP, Fan SR, Bai FY, Li J, Liao QP. (2008). Antifungal susceptibility and genotypes of *Candida albicans* strains from patients with vulvovaginal candidiasis. *Mycoses*, 52, 24-28.

Lockhart S.R, Vargas K, Swails-Wenger J, Enger L, Soll DR (1999). Natural defenses against *Candida* colonization Breakdown in oral cavities of the elderly. *Journal of Dental Research*. 78(4).

- Loster JE, Wieczorek A, Loster BW (2016). Correlation between age and gender in *Candida* species infection of complete denture wearers a retrospective analysis. *Clinical interventions in aging*. 11:1707-1714.
- Lynch DP. (1994). Oral candidiasis. *Oral Surgery, Oral Medicine, Oral Pathology*, 78(2), 189–193. doi: 10.1016/0030-4220(94)90146.
- Ma L Xie L, Dong X, Shi W. (2009). Role of extracellular phospholipase B of *Candida albicans* as a virulent factor in experimental keratomycosis. *Sep*; 34(9):761-8.
- Majima T, S. Ito-Kuwa, R. Nagatomi and K. Nakamura, (2014). "Study of the oral carriage of *Candida* sp. in dental students and staff—Identification of *Candida* sp. and background survey." *Oral Science International* 11(1): 30-34.
- Mahmoudabadi, A. Z., M. Zarrin and N. Kiasat. (2014). "Biofilm formation and susceptibility to amphotericin B and fluconazole in *Candida albicans*." *Jundishapur journal of microbiology* 7(7).
- Manns JM, Mosser DM, and Buckley HR. (1994). Production of a hemolytic factor by *Candida albicans*. *Infect Immune*, 62(11):5154–6.
- Manfredi M, McCullough MJ, Vescovi P, Al-Kaarawi ZM, Porter SR. (2004). Update on diabetes mellitus and related oral diseases. *Oral Dis*. 2004; 10:187–200.
- Malcok HK, E. Aktas A, Ayyildiz, N Yigit and H Yazgi. (2009). "Hemolytic activities of the *Candida* species in liquid medium." *The Eurasian journal of medicine* 41(2): 95.
- Mayer FL, Wilson D, Hube B. (2013). *Candida albicans* pathogenicity mechanisms. *Virulence*. 4(2): 119–128.

- Mayo Clinic. Diseases and Conditions: Yeast infection (vaginal). [<http://www.mayoclinic.org/diseases-conditions/yeast-infection/basics/definition/con-20035129>].
- Mikulska M, Bono VD, Ratto S, Viscoli C. (2012). Occurrence, Presentation and Treatment of Candidemia. *Expert Review of Clinical Immunology*. 8(8):755-765.
- Mohammadi F, Javaheri MR, Nekoeian S, Dehghan P. (2016). Identification of Candida species in the oral cavity of diabetic patients. *Curr Med Mycol*, 2(2):1-7.
- Murciano C, Moyes DL, Runglall M, Tobouti P, Islam A, Hoyer LL, Naglik JR. (2012). Evaluation of the Role of Candida albicans Agglutinin-Like Sequence (Als) Proteins in Human Oral Epithelial Cell Interactions. *PLoS One*. 7(3): e33362.
- Naglik JR, Rodgers CA, Shirlaw PJ, Dobbie JL, Fernandes-Naglik LL, Greenspan D, Agabian N, Challacombe SJ (2003). Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlate with active oral and vaginal infections, *J Infect Dis*; 188:469-79
- Napenas JJ, Brennan MT, Fox PC, Napenas JJ, Brennan MT, & Fox PC. (2009). Diagnosis and treatment of xerostomia (dry mouth). *Odontology / the Society of the Nippon Dental University*, 97(2), 76–83. Doi: 10.1007/s10266-008- 0099.
- National Committee for Clinical Laboratory Standards, *Methods for Antifungal Disk Diffusion Susceptibility Testing of Yeasts: Approved Standard M44-A*, 2004Wayne, PA, USANCCLS.
- NCCLS. *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Second Edition*. NCCLS document, M27-A2.

- Nguyen MH, Peacock JE Jr, Tanner DC, Morris AJ, Nguyen ML, Snyderman DR, Wagener MM, Yu VL (1995). Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. *Archives of Internal Medicine*. 155(22):2429-35.
- Obradovic R R., L. G. Kesic, A. N. Pejicic, M. S. Petrovic, N. D. Zivkovic and D. M. zivkovic (2011). "Diabetes mellitus and oral candidiasis." *Acta Stomatologica Naissi* 27(63): 1025-1034.
- Ozkan S, Kaynak, F, Kalkanci, A, Abbasoglu U. and Kustimur S (2005). Slime production and proteinase activity of *Candida* species isolated from blood samples and the comparison of these activities with minimum inhibitory concentration values of antifungal agents. *Mem Inst Oswaldo Cruz*, 100, 319–323.
- Pallavan B, V. Ramesh, B. P. Dhanasekaran, N. Oza and V. Govindarajan (2014). "Comparison and correlation of candidal colonization in diabetic patients and normal individuals." *Journal of Diabetes & Metabolic Disorders* 13(1): 66.
- Pappas PG, Kauffman CA, Andes D, Benjamin DK., Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. (2009). Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. *Clinical Infectious Diseases*. 48 (5): 503-535.
- Pathak AK, Jain NR, Joshi R (2012). Antibiogram of *Candida* species isolated from mono and multi-species oral candidal carriage using disk diffusion method. *Saudi J Health Sci*; 1:132-8.
- Paula VS, Eunice TG, Ewerton GO, Carlos EV (2011). *Candida* Spp. prevalence in well controlled type 2 diabetic patients with denture stomatitis. *OOOOE*. 2011; 111: 726-33.

- Pfaller MA, Diekema DJ (2007). Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. *Virulence*. (2): 119–128.
- Pierce CG, Uppuluri P, Tristan AR, Wormley JR, Mowat E., Ramage G, López-Ribot JL (2008). A simple and reproducible 96 well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. *Nat. Protoc.*, 3(9), 1494-1500.
- Prevention.Candidiasis.<http://www.prevention.com/healthconditions/candidiasis#Prevention>>].
- Public Health Agency of Canada. *Candida albicans* - Material Safety Data Sheets.[<http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/msds30e-eng.php>>].
- Rajan S, Sadeq A, Deepti S, Noorliza M, Abdul Rashid I (2010). Oral mucosal lesions in non-oral habit diabetic patients and association of diabetes mellitus with oral precancerous lesions. *Diabetes Res Clin Pract*; 83(3): 320-2.
- Ramage G, Martínez JP, López-Ribot JL (2006). *Candida* biofilms on implanted biomaterials: a clinically significant problem. *FEMS Yeast Res*, 6, 979-986.
- Reichart PA, Samaranayake LP, & Philipsen HP (2000). Pathology and clinical correlates in oral candidiasis and its variants: a review. *Oral diseases*, 6(2), 85-91.
- Robertson, Douglas Paul (2011) Oral complications of Type 1 diabetes mellitus in a non-smoking population. PhD thesis.
- Romani L. (2000). Innate and adaptive immunity in *Candida albicans* infections and saprophytism. *Journal of Leukocyte Biology*. 68(2): 175-179.

- Sachin CD, Ruchi K, Santosh S (2012). In vitro evaluation of proteinase, phospholipase and haemolysin activities of *Candida* species isolated from clinical specimens. *International journal of medicine and biomedical research*. 1(2).
- Salvo D (2009). *Microbiology and Immunology*. chapter3. Mycology, The University of South Carolina, USA.
- Salyers A (1994). Witt D. Virulence factors that damage the host. In: Salyers A, Witt D, editors. *Bacterial pathogenesis: a molecular approach*. Washington, D.C.: ASM Press; pp. 47–62.
- Samaranayake LP, Cheung LK, & Samaranayake YH (2002). Candidiasis and other fungal diseases of the mouth. *Dermatologic Therapy*, 15(3), 251–269. doi:10.1046/j.1529-8019.2002.01533.x
- Samaranayake LP, Raeside JM & MacFarlane TW (1984). Factors affecting the phospholipase activity of *Candida* species in vitro. *Sabouraudia* 22, 201–207.
- Sanglard D, Ischer, F, Parkinson, T, Falconer, D, & Bille J (2003). *Candida albicans* mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. *Antimicrobial Agents and Chemotherapy*, 47(8), 2404- 2412.
- Schaller M, Korting HC, Borelli C, Hamm G, Hube B (2005). *Candida albicans*-secreted aspartic proteinases modify the epithelial cytokine response in an in vitro model of vaginal candidiasis. *Infect Immun*; 73:2758-65.
- Scully C. (2003). Drug effects on salivary glands: dry mouth. *Oral Diseases*, 9(4), 165–76.

- Sharma S, Kaur H, & GK K (2001). Cell cycle effects of the phenothiazines: trifluoperazine and chlorpromazine in *Candida albicans*. *FEMS Microbiology Letters*, 199(2), 185–190.
- Sharma U, Patel K, Shah V, Sinha S, Pratap V, Rathore VPS (2017). Isolation and Speciation of *Candida* in Type II Diabetic Patients using CHROM Agar. *Journal of Clinical and Diagnostic Research*, 11(8), 9-11.
- Sharon V & Fazel N (2010). Oral candidiasis and angular cheilitis. *Dermatologic Therapy*, 23(3), 230–242. doi:10.1111/j.1529-8019.2010.01320.x
- Ship JA (2003). Diabetes and oral health an overview. *J Am Dent Asso.*134:4S-10.
- Silva S, Negri M, Henriques M, Oliveira R., Williams D W & Azeredo J (2011). *Candida glabrata*, *Candida parapsilosis* and *Candida tropicalis*: biology, epidemiology, pathogenicity and antifungal resistance. *FEMS Microbiol Rev*, 36, 288–305.
- Siribang PK, Tongchat S, Soisiri T, Somsak M, Umawadee C, Weerapan K (2009). Xerostomia, hyposalivation, and oral microbiota in type 2 diabetic patients: A preliminary study. *J Med Assoc Thai*; 92(9): 1220-8.
- Sobel JD (1984). Critical role of germination in the pathogenesis of experimental candidal vaginitis. *Infect Immun*, 44:576.
- Soysa NS, Samaranayake LP and Ellepola ANB (2005). Diabetes mellitus as a contributory factor in oral candidosis. *Diabetes Medicine*; 23:455-459.
- Subramanya SH, Baral B P, Sharan NK, Nayak N, Metok Y, Sathian B, Bairy I, and Gokhale S (2017). Antifungal susceptibility and phenotypic virulence markers of *Candida* species isolated from Nepal. *BMC Research Notes*, 10:543, 1-7.

- Sudbery P, Gow N, Berman J (2004). The distinct morphogenic states of *Candida albicans*. *Trends in Microbiology*. 12(7):317-24.
- Sykes LM, Sukha A (2001). Potential risk of serious oral infections in the diabetic patients: a clinical report. *J Prosthet Dent*; 86: 569-73.
- Talabani AN, Kim CL, Kiat AOH, Ismail AR, Chinna K. (2013). The prevalence of *Candida* spp. in the saliva of controlled and uncontrolled diabetes mellitus type II patients. *J Bagh College Dentistry* Vol. 25(4).
- Touger H. (1996). *Dental Care and Patients with Diabetes*. Gaithersburg, US: Gaithersburg Aspen publishers.
- Tsang, C., F. Chu, W. Leung, L. Jin, L. Samaranayake and S. Siu (2007). Phospholipase, proteinase and haemolytic activities of *Candida albicans* isolated from oral cavities of patients with type 2 diabetes mellitus. *Journal of medical microbiology* 56(10): 1393-1398.
- Wachtler B, Citiulo F, Jablonowski N, Förster S, Dalle F, Schaller M (2012). *Candida albicans*-epithelial interactions: dissecting the roles of active penetration, induced endocytosis and host factors on the infection process. *PLoS One*. 7:e36952.
- Wachtler B, Wilson D, Haedicke K, Dalle F, Hube B (2011). From Attachment to Damage: Defined Genes of *Candida albicans* Mediate Adhesion, Invasion and Damage during Interaction with Oral Epithelial Cells. *PLoS One*. 6(2): e17046.
- White TC, Holleman S, Dy F, Mirels LF, & Stevens DA (2002). Resistance Mechanisms in Clinical Isolates of *Candida albicans*. *Antimicrobial Agents And Chemotherapy*, 46(6), 1704–1713. doi:10.1128/aac.46.6.1704-1713.
- WHO (1994). WHO Technical Report Series. Prevention of Diabetes mellitus; Geneva.


Williams D, & Lewis M (2011). Pathogenesis and treatment of oral candidosis. *Journal of Oral Microbiology*, 1–11. doi:10.3402/jom.v3i0.5771.

Wisplinghoff H Bischoff T Tallent SM (2004). Nosocomial bloodstream infections in U.S. hospitals: analysis of 24179 cases from a prospective nationwide surveillance study *Clin Infect Dis*, 39 309- 17.


Xie Z, Thompson A, Sobue T, Kashleva H, Xu H, Vasilakos J, Dongari-Bagtzoglou A (2012). *Candida albicans* biofilms do not trigger reactive oxygen species and evade neutrophil killing. *The Journal of Infectious Diseases*. 206(12):1936-45.




Photograph No.1 Colonies of *Candida* from Healthy (left) and Diabetic (Right)



Photograph No.2 Biofilm of *Candida albicans* in Microtitre wells



Photograph No.3 Antifungal Susceptibility Test



Photograph No.4 Hemolysis Degree. SDBwG (Right) and SDBwoG (Left)



Photograph No.5: Sample collection



Photograph No.6: Sample processing in the Microbiology Lab